WO2005073720A3 - Method of screening for new drugs - Google Patents

Method of screening for new drugs Download PDF

Info

Publication number
WO2005073720A3
WO2005073720A3 PCT/GB2005/000356 GB2005000356W WO2005073720A3 WO 2005073720 A3 WO2005073720 A3 WO 2005073720A3 GB 2005000356 W GB2005000356 W GB 2005000356W WO 2005073720 A3 WO2005073720 A3 WO 2005073720A3
Authority
WO
WIPO (PCT)
Prior art keywords
bax
nucleophosmin
screening
new drugs
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/000356
Other languages
French (fr)
Other versions
WO2005073720A2 (en
Inventor
John Sharkey
Lorraine Elizabeth Kerr
Duncan Matthew Short
Jui-Lee Andrea Birse-Archbold
Jane Victoria Thompson
Ailsa Lynn Mcgregor
James Mcculloch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of WO2005073720A2 publication Critical patent/WO2005073720A2/en
Publication of WO2005073720A3 publication Critical patent/WO2005073720A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for identifying compounds that are effective in modulating the binding of nucleophosmin to Bax (Bcl-2-associated X protein). Nucleophosmin has been found to regulate the activity of Bax. The interaction between Bax and nucleophosmin is used in a method for the screening of new drugs for the treatment of disorders that involve Bax-mediated cell death. A kit for assaying the interaction between Bax and nucleophosmin is also provided. Compounds identified by the aforementioned method are used for the manufacture of medicaments for treating cerebral and myocardial ischaemic injury, neonatal hypoxic brain injury, traumatic brain injury and other neurological disorders.
PCT/GB2005/000356 2004-02-02 2005-02-02 Method of screening for new drugs Ceased WO2005073720A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0402269.5 2004-02-02
GB0402269A GB0402269D0 (en) 2004-02-02 2004-02-02 Method of screening for new drugs

Publications (2)

Publication Number Publication Date
WO2005073720A2 WO2005073720A2 (en) 2005-08-11
WO2005073720A3 true WO2005073720A3 (en) 2005-10-20

Family

ID=31985501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/000356 Ceased WO2005073720A2 (en) 2004-02-02 2005-02-02 Method of screening for new drugs

Country Status (2)

Country Link
GB (1) GB0402269D0 (en)
WO (1) WO2005073720A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561073C (en) 2004-03-27 2014-01-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLOMBO EMANUELA ET AL: "Nucleophosmin regulates the stability and transcriptional activity of p53", NATURE CELL BIOLOGY, vol. 4, no. 7, July 2002 (2002-07-01), pages 529 - 533, XP002335109, ISSN: 1465-7392 *
OLTVAI Z N ET AL: "BCL-2 HETERODIMERIZES IN VIVO WITH A CONSERVED HOMOLOG, BAX, THAT ACCELERATES PROGRAMED CELL DEATH", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 74, 27 August 1993 (1993-08-27), pages 609 - 619, XP002018918, ISSN: 0092-8674 *
PERKINELMER: "A Practical Guide to Working with AlphaScreenTM", INTERNET ARTICLE, April 2003 (2003-04-01), XP002316832 *

Also Published As

Publication number Publication date
GB0402269D0 (en) 2004-03-10
WO2005073720A2 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
EP1990338A3 (en) Biphenylcyclopropylamides as p-38 Kinase inhibitors
WO2005000894A3 (en) Binding molecules for the treatment of myeloid cell malignancies
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
WO2005107802A3 (en) Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
WO2007061750A3 (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
WO2006037016A3 (en) Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2005051308A3 (en) Methods of treating diseases and disorders by targeting multiple kinases
WO2008011083A3 (en) Compounds for enhancing arginase activity and methods of use thereof
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2008080045A3 (en) Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2008135983A3 (en) Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2010018996A3 (en) Human neural stem cell, and pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same
TR200001471T2 (en) Use of aminomethyl-chroma substitute for the prevention of nerve cell degeneration and regeneration of nerve cells.
WO2005115548A3 (en) Treating depressive disorders with carbonic anhydrase activators
WO2006014999A3 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
PL1715890T3 (en) Ctgf as target for the therapy of microalbuminuria in patients with diabetic nephropathy
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2003039487A3 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2007035722A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
Agostinho et al. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain
ATE546733T1 (en) THERAPY STRATEGY FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND DEGENERATIVE DISEASES
WO2008009868A3 (en) Methods and tools for the therapy of neurodegenerative pathologies
DE602004013540D1 (en) INHIBITION OF THE CD95 LIGAND / RECEPTOR SYSTEM FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES AND INJURIES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase